loading...| Preferred Name |
interferon gamma-1b |
|
| Synonyms |
recombinant interferon gamma-1b |
|
| Definitions |
A recombinant form of the endogenous cytokine interferon-gamma (IFN-gamma; IFNg), with a peptide length of 140 amino acids and modified with an N-terminal methionyl group, with potential immunomodulating and antineoplastic activities. Upon administration, IFNg-1b binds to IFNg cell surface receptors (IFNGRs), activates IFNg-stimulated signaling pathways, including the JAK-STAT pathway, and leads to the transcription of multiple IFNg-controlled genes, the expression of which may activate certain components of the immune system. IFNg activates natural killer (NK) cells, macrophages, and cytotoxic T lymphocytes (CTLs), stimulates antibody-dependent cellular cytotoxicity (ADCC) and induces the expression of major histocompatibility complex (MHC) molecules, which leads to an increase in antigen presentation, including tumor-associated antigens (TAAs), to the immune system, and modulates the expression of certain pro-inflammatory cytokines by antigen-presenting cells (APCs). Altogether, this increases tumor cell killing. IFNg-1b, a cell-signaling protein, plays a key role in the regulation and activation of the immune system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C100089" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C100089" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000784898 |
|
| altLabel |
recombinant interferon gamma-1b N(sup 2)-L-methionyl-1-139-interferon G Actimmune |
|
| CAS Registry |
98059-61-1 |
|
| cui |
C0813623 C1579322 C0021741 |
|
| DATE FIRST PUBLISHED |
2016-11-09 |
|
| Date last modified |
2016-12-06 |
|
| definition |
A recombinant form of the endogenous cytokine interferon-gamma (IFN-gamma; IFNg), with a peptide length of 140 amino acids and modified with an N-terminal methionyl group, with potential immunomodulating and antineoplastic activities. Upon administration, IFNg-1b binds to IFNg cell surface receptors (IFNGRs), activates IFNg-stimulated signaling pathways, including the JAK-STAT pathway, and leads to the transcription of multiple IFNg-controlled genes, the expression of which may activate certain components of the immune system. IFNg activates natural killer (NK) cells, macrophages, and cytotoxic T lymphocytes (CTLs), stimulates antibody-dependent cellular cytotoxicity (ADCC) and induces the expression of major histocompatibility complex (MHC) molecules, which leads to an increase in antigen presentation, including tumor-associated antigens (TAAs), to the immune system, and modulates the expression of certain pro-inflammatory cytokines by antigen-presenting cells (APCs). Altogether, this increases tumor cell killing. IFNg-1b, a cell-signaling protein, plays a key role in the regulation and activation of the immune system. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C100089" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C100089" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C100089 |
|
| notation |
CDR0000784898 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
interferon gamma-1b |
|
| tui |
T116 T129 T121 |